Patient Resources
Lung SPORE Clinical Trials
Fred Hutchinson Cancer Center's Specialized Program of Research Excellence (SPORE) in Lung Cancer was awarded by the National Cancer Institute in August of 2019 to support groundbreaking research that translates directly into improved prevention, detection, and treatment for patients. SPORE awards are intended to prevent new cases of cancer, as well as improve survival and quality of life for current patients. Key elements of the program are interdisciplinary collaboration, resource sharing, and inclusion of patient advocates on the research team.
The Fred Hutch Lung SPORE will support three upcoming clinical trials opening for patient enrollment in 2021. Our clinical trials will feature new treatments in immunotherapy, such as checkpoint inhibitors and cancer vaccines, intended to help patients’ own immune systems fight their cancer more effectively.
Lung Clinical Trials Opening in 2021
Exploring a treatment to enhance immune checkpoint inhibitor therapy for patients with NSCLC
- This is a Phase 2 study of SX-682 (a CXCR1/2 inhibitor) treatment in combination with anti-PD1 antibody therapy.
- Enrolling patients with non-small cell lung cancer (NSCLC) who have previously failed immune checkpoint inhibitor therapy.
Developing a personalized T-cell vaccine for lung cancer immunotherapy
- This is a Phase 1 study to evaluate the safety and effectiveness of a personalized vaccine made of genetically modified T-cells to target the patient’s tumor.
- Enrolling patients with stage IV non-small cell lung cancer (NSCLC) that has progressed despite treatment with PD-1 therapy.
Studying a new LSD1 inhibitor therapy for patients with SCLC
- This trial will evaluate the response rate in small cell lung cancer (SCLC) patients treated with ORY1001, a novel LSD1 antagonist.
- Enrolling patients with SCLC who were previously treated with chemotherapy and immunotherapy in the first and/or second line setting.
Research Studies
Fred Hutch patients can also participate in our Lung SPORE research studies by donating small samples of blood, plasma, or lung biopsy tissue during the course of their treatment. These specimens and patient data (such as age and tumor type) can be critically important in studying:
- Mechanisms of disease
- Analyzing patient outcomes
- Identifying potential therapies for lung cancer treatment.
Our researchers use this information to help design future clinical trials.
Talk to your doctor about how you can contribute to lung cancer research.
Find a Doctor
Our Lung SPORE investigators are treating physicians at Fred Hutchinson Cancer Center and University of Washington.
McGarry Houghton, MD
Christina Baik, MD, MPH
Sylvia Lee, MD
Rafael Santana-Davila, MD
"I'm most excited about the opportunities to finally offer lung cancer patients in Seattle the very best science coming out of Fred Hutch. We can now take the best homegrown ideas from our labs and bring them to the clinic, bypassing the shortcomings of current therapies."
Dr. McGarry Houghton
Our Patient Advocates
The inclusion of patient advocates is a crucial element of our Lung SPORE. Our experienced patient advocates provide assurance that our clinical trials are designed to provide a meaningful patient impact. They also assist with outreach to the lung cancer patient community and assist with recruitment of patients to our research protocols and clinical trials.
Janet Freeman-Daily
Ms. Freeman-Daily is a metastatic lung cancer patient diagnosed in May 2011. Her self-advocacy enabled her to obtain biomarker testing that found the ROS1 gene alteration driving her tumor. This led her to enroll in a clinical trial at the University of Colorado, where she became a patient advocate on their Lung SPORE. Janet, a retired Boeing engineer in the Seattle area, now focuses on translating the science and experience of lung cancer for others. She blogs at Gray Connections, is a leader of The ROS1ders patient group, co-hosts #LCSM (Lung Cancer Social Media) Chat on Twitter, speaks at international cancer conferences, and is helping to develop the IASLC STARS (Supportive Training for Advocates in Research and Science) program.
Pam Moffitt
Ms. Moffitt is a >15-year survivor of Stage IV NSCLC squamous cell. She received her treatment at the Mayo Clinic in Rochester and initially became involved in advocacy programs there. Since that time, Pam has become involved in numerous review panels, including for the Department of Defense and the FDA. She is particularly interested in the informed consent process. Ms. Moffitt also is an advocate of lung cancer early detection programs and maintains an interest in the emotional cost that undiagnosed lung cancer can have on patients enrolled in lung cancer screening protocols.
Larry Mitchell
Mr. Mitchell is a long-term survivor of small cell lung cancer (SCLC), a disease subtype for which there are few patient advocates. Mr. Mitchell brings his experience in this arena to assist the guidance of Project #3, which seeks to perform a clinical trial employing a novel therapeutic for SCLC patients.
Patient Resources
Prospective lung cancer patients, their families and their caregivers need information on cancer, treatment options, access to care and supportive services. The resources listed below are a good place to start, along with Fred Hutch's Patient Treatment & Support information.